-+ 0.00%
-+ 0.00%
-+ 0.00%
SLS Bio Corrects Cash Flow Statement for Omitted Asset Purchases
Share
Listen to the news
SLS Bio Corrects Cash Flow Statement for Omitted Asset Purchases
  • SLS Bio corrected its January-September 2026 cash flow statement on November 16 to reflect omitted facility acquisition spending of KRW 37.3 million.
  • Property, plant and equipment purchases rose to KRW 500.04 million from KRW 462.74 million.
  • Net investing cash inflow fell to KRW 2.61 billion from KRW 2.65 billion.
  • Ending cash and cash equivalents declined to KRW 574.5 million from KRW 611.8 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SLS Bio Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261116002244), on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending